Beta
Back to RXRX.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • EPS
  • EPS Diluted
  • Revenue
  • Operation Income
  • Net Income
  • Operating Expenses
  • Cash Flow
  • Cash & Debt
  • Current Contract Liabilities
operating-expenses-chart

RXRX Operating Expenses

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

In Q4'25, total operating expenses for RXRX reached $129.6M USD, comprising $95.9M USD in R&D expenses and $33.7M USD in SG&A expenses, reflecting a decline from the prior quarter's peak. From Q1'23 to Q4'25, R&D expenses exhibited strong growth, rising from $46.7M USD to a high of $129.6M USD in Q1'25 before tapering to $95.9M USD, indicating an overall upward trend with a recent moderation; meanwhile, SG&A expenses increased steadily from $22.9M USD to $77.2M USD in Q4'24, followed by a notable decline to $33.7M USD, suggesting cost optimization efforts in administrative functions amid fluctuating R&D investments. The stacked bar chart highlights R&D as the dominant component, driving total expenses from $69.5M USD in Q1'23 to a peak of $184.3M USD in Q1'25, with volatility underscoring potential expansion phases in the biotech sector.